作为全球肿瘤领域顶级学术盛会，2026 年欧洲肿瘤内科学会年会（ESMO Congress 2026）将于当地时间 10 月 23 日至 27 日于西班牙马德里启幕。7 月 17 日，ESMO 官方已正式公布本届会议中常规摘要及讲者信息。【肿瘤资讯】特梳理 Proffered Paper Session、Rapid Oral Session 中泌尿生殖系统肿瘤相关专场临床研究，带您一文速览前沿资讯。
Proffered paper 1: Genitourinary tumour, renal and urothelial
摘要号：4733O
标题：Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
中文标题：顺铂不耐受肌层浸润性膀胱癌患者围手术期帕博利珠单抗单药或维恩妥尤单抗联合帕博利珠单抗治疗：KEYNOTE-905研究事后分析
讲者：Anders Ullén (Stockholm, Sweden)
摘要号：4734O
标题：ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
中文标题：3期KEYNOTE-B15研究循环肿瘤DNA分析：维恩妥尤单抗联合帕博利珠单抗用于可耐受顺铂的肌层浸润性膀胱癌患者的新辅助及辅助治疗
讲者：Jonathan A. Chatzkel (Tampa, United States of America)
Proffered paper 2: Genitourinary tumours, renal and urothelial
摘要号：3586O
标题：First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study
中文标题：晚期肾细胞癌（RCC）的一线治疗：帕博利珠单抗+仑伐替尼+贝组替凡，或MK-1308A+仑伐替尼的随机、开放标签、3期LITESPARK-012研究
讲者：Toni K. Choueiri (Boston, United States of America)
摘要号：3587O
标题：Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy
中文标题：3期LITESPARK-011研究的最终分析：贝组替凡（bel）联合仑伐替尼（len）对比卡博替尼（cabo）用于抗PD-(L)1治疗后的晚期肾细胞癌（RCC）
讲者：Daniel Y. Heng (Calgary, Canada, OH)
摘要号：3588O
标题：Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)
中文标题：XmAb819（一种新型ENPP3×CD3双特异性抗体）在晚期透明细胞肾细胞癌（ccRCC）中的1期研究结果
讲者：Sumanta K. Pal (Duarte, United States of America)
摘要号：4735O
标题：Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
中文标题：围手术期帕博利珠单抗（pembro）或安慰剂（pbo）联合新辅助顺铂（cis）和吉西他滨（gem）治疗肌层浸润性膀胱癌（MIBC）受试者的双盲、3期KEYNOTE-866研究
讲者：Jens Bedke (Stuttgart, Germany)
摘要号：4736O
标题：Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
中文标题：一项3期试验结果：新辅助化疗单用对比新辅助化疗联合纳武利尤单抗、随后术后辅助纳武利尤单抗治疗肌层浸润性膀胱癌（MIBC）患者
讲者：Andrea Necchi (Milan, Italy)
Rapid oral 1: Genitourinary tumours, renal and urothelial
摘要号：4737RO
标题：Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POTOMAC
中文标题：度伐利尤单抗（D）联合BCG诱导和维持治疗（I+M）用于未接受过BCG治疗的高危非肌层浸润性膀胱癌（NMIBC）：仅乳头状肿瘤患者的早期复发率和免膀胱切除生存率——来自POTOMAC研究
讲者：Maria De Santis (Berlin, Germany)
摘要号：4738RO
标题：Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study
中文标题：3期KEYNOTE-B15研究中，适合顺铂治疗的肌层浸润性膀胱癌（MIBC）受试者接受新辅助和辅助（neoadj-adj）维恩妥尤单抗（EV）联合帕博利珠单抗（pembro）治疗的健康相关生活质量评分（HRQoL）
讲者：Alfonso Gomez de Liano Lista (Las Palmas de Gran Canaria, Spain)
摘要号：4739RO
标题：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
中文标题：芦康沙妥珠单抗（Sac-TMT）联合帕博利珠单抗（Pembro）治疗局部晚期或转移性尿路上皮癌（la/mUC）：一项2期研究（2870-002/SKB264-II-06）的结果
讲者：卞晓洁 (复旦大学附属肿瘤医院)
摘要号：4740RO
标题：Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
中文标题：维恩妥尤单抗（EV）联合或不联合帕博利珠单抗（P）一线治疗不适合顺铂的局部晚期或转移性尿路上皮癌（la/mUC）：EV-103研究队列DE/A和K的长期随访分析
讲者：Jose Pablo Maroto Rey (Barcelona, Spain)
摘要号：4741RO
标题：Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) From NIAGARA
中文标题：肌层浸润性膀胱癌（MIBC）患者分子亚型及其与治疗结局相关性的探索性分析——来自NIAGARA研究
讲者：Matthew D. Galsky (New York, United States of America)
摘要号：4742RO
标题：Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
中文标题：戈沙妥珠单抗（SG）联合维恩妥尤单抗（EV）和赛帕利单抗（ZIM）用于初治转移性尿路上皮癌（mUC）：1b期TROPHY-U-01研究队列7的中期结果
讲者：Randy Sweis (Chicago, United States of America)
Rapid oral 2: Genitourinary tumours, renal and urothelial
摘要号：3589RO
标题：Final protocol-prespecified analysis of the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab versus placebo in clear cell renal cell carcinoma (ccRCC)
中文标题：3期KEYNOTE-564试验中帕博利珠单抗辅助治疗对比安慰剂治疗透明细胞肾细胞癌（ccRCC）的最终方案预设分析
讲者：Toni K. Choueiri (Boston, United States of America)
摘要号：3590RO
标题：Patient reported outcomes in resected renal cell carcinoma: adjuvant durvalumab versus active monitoring in the RAMPART trial
中文标题：切除术后肾细胞癌患者报告结局：RAMPART试验中辅助度伐利尤单抗与主动监测的比较
讲者：Sophie Merrick (London, United Kingdom)
摘要号：3591RO
标题：First results of SWOG S2200, a randomized, phase II study comparing cabozantinib with or without atezolizumab in metastatic papillary renal cell carcinoma (mPRCC)
中文标题：随机II期SWOG S2200研究的初步结果：卡博替尼±阿替利珠单抗在转移性乳头状肾细胞癌中的比较
讲者：Benjamin L. Maughan (San Antonio, United States of America)
摘要号：3592RO
标题：Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib/II Study
中文标题：AK112（依沃西单抗，PD-1/VEGF双特异性抗体）一线治疗IMDC有利风险晚期肾细胞癌的疗效和安全性：Ib/II期研究结果
讲者：鄢谢桥 (北京大学肿瘤医院)
摘要号：3593RO
标题：Plasma Kidney Injury Molecule-1 (KIM-1) Dynamics During First-Line Immunotherapy With or Without Cabozantinib in Advanced Renal Cell Carcinoma (aRCC)
中文标题：晚期肾细胞癌（aRCC）一线免疫治疗联合或不联合卡博替尼期间血浆肾损伤分子-1（KIM-1）的动态变化
讲者：Wenxin Xu (Boston, United States of America)
摘要号：3594RO
标题：Feasibility and reproducibility of PD-L1 assessment within the CARE1: a phase III, randomized, biomarker-driven pragmatic trial to optimize first line treatment in patients (pts) with metastatic clear-cell renal cell carcinoma (mRCC)
中文标题：CARE1试验中PD-L1评估的可行性和可重复性：一项III期、随机、生物标志物驱动的实用性试验，旨在优化转移性透明细胞肾细胞癌（mRCC）患者的一线治疗
讲者：Ronan Flippot (Villejuif, France)
摘要号：3595RO
标题：Relationship between health-related quality of life (HRQoL) and efficacy in LITESPARK-011: belzutifan (bel) + lenvatinib (lenva) versus cabozantinib (cabo) in advanced clear cell renal cell carcinoma (ccRCC) after anti–PD-(L)1 therapy
中文标题：LITESPARK-011研究中健康相关生活质量（HRQoL）与疗效的关系：贝组替凡（bel）联合仑伐替尼（lenva）对比卡博替尼（cabo）用于抗PD-(L)1治疗后的晚期透明细胞肾细胞癌（ccRCC）
讲者：Daniel Y. Heng (Calgary, Canada, OH)
Proffered paper: Genitourinary tumours, prostate, penile and testils
摘要号：2215O
标题：Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC)
中文标题：3期PEACE-1试验中醋酸阿比特龙联合泼尼松治疗新发转移性去势敏感性前列腺癌（mCSPC）的长期总生存期
讲者：Karim Fizazi(Lille, France)
摘要号：2216O
标题：Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted RIPTAC™ at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features
中文标题：评估JNJ-6143（首创口服AR靶向RIPTAC™）在最佳剂量下用于mCRPC/mAPMR（含高危分子特征）患者的安全性与疗效
讲者：Benjamin Garmezy(Nashville, United States of America)
摘要号：2045O
标题：Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically very high risk prostate cancer (PCa)
中文标题：采用转录组分类器进行风险分层并联合雄激素受体通路抑制剂强化治疗临床极高危前列腺癌
讲者：Sarah Howlett(London, United Kingdom)
Rapid oral: Genitourinary tumours, prostate, penile and testils
摘要号：1209RO
标题：Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial
中文标题：新辅助特瑞普利单抗联合化疗用于局部晚期阴茎鳞状细胞癌：一项多中心、前瞻性、单臂II期临床试验
讲者：韩辉 (中山大学肿瘤防治中心)
摘要号：1210RO
标题：Safety and Efficacy of Ixotatug Vedotin (TORL-1-23), a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors (GCT)
中文标题：靶向Claudin 6的抗体药物偶联物Ixotatug Vedotin（TORL-1-23）单药治疗生殖细胞肿瘤的安全性与疗效
讲者：Caspian Oliai (Los Angeles, United States of America)
摘要号：2217RO
标题：Updated results from the phase 1b/2 KEYNOTE-365 cohort I: pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
中文标题：KEYNOTE-365研究队列I（1b/2期）的更新结果：帕博利珠单抗联合卡铂及依托泊苷化疗对比单纯化疗在神经内分泌前列腺癌中的应用
讲者：Gunhild Von Amsberg (Hamburg, Germany)
摘要号：2218RO
标题：Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
中文标题：液体活检中区分克隆性造血与肿瘤同源重组修复改变的意义及其对PARP抑制剂治疗转移性去势抵抗性前列腺癌的指导价值
讲者：Emmanuel S. Antonarakis (Minneapolis, United States of America, MD)
摘要号：2219RO
标题：Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)
中文标题：ctDNA肿瘤分数（TF）作为预后生物标志物在TALAPRO-3研究中的应用价值：一项比较他拉唑帕利（TALA）+恩扎卢胺（ENZA）与安慰剂（PBO）+ENZA在携带同源重组修复（HRR）基因突变的转移性去势敏感性前列腺癌（mCSPC）患者中的3期研究
讲者：Arun A. Azad (Melbourne, Australia)
摘要号：2220RO
标题：Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
中文标题：血浆ctDNA单独检测或作为肿瘤组织检测的补充，用于转移性去势抵抗性前列腺癌（mCRPC）的HRR和PI3K/AKT基因分型：PROMPT研究（NCT04746300）
讲者：Niven Mehra (Nijmegen, Netherlands, Surrey)
摘要号：2221RO
标题：Patient Reported Quality of Life (QoL) for Docetaxel (Doc) vs Lutetium177-617-PSMA (LuP) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from the Canadian Cancer Trials Group (CCTG) PR21 Trial
中文标题：患者报告的生活质量（QoL）：多西他赛（Doc）对比镥-177-PSMA-617（LuP）治疗转移性去势抵抗性前列腺癌（mCRPC）——来自加拿大癌症试验组（CCTG）PR21试验的结果
讲者：Daniel Khalaf (Toronto, Canada)
摘要号：2222RO
标题：Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study
中文标题：转移性去势敏感性前列腺癌（mCSPC）且携带同源重组修复（HRR）基因改变的患者接受他拉唑帕利（TALA）+恩扎卢胺（ENZA）对比安慰剂（PBO）+ENZA治疗的患者报告结局（PROs）：3期TALAPRO-3研究结果
讲者：Arun A. Azad (Melbourne, Australia)
（官网持续更新中，如有疏漏，欢迎补充）
排版编辑：肿瘤资讯-云初
苏公网安备32059002004080号
